Ireland· IE-PA-EU/1/17/1196/003-008
Kevzara 200 mg solution for injection in pre-filled syringe
A sarilumab product containing sarilumab, registered in Ireland by Sanofi Winthrop Industrie. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Sarilumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC14 (sarilumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Sarilumab · ATC L04AC14
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sarilumab costs, country by country.
Normalised to the WHO defined daily dose (14.3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sarilumab · price per daily dose (14.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$60.91
The record
At a glance
HPRA (Ireland)- Active substance
- Sarilumab
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Ireland (IE)
- ATC code
- L04AC14
- ATC class
- Sarilumab
- Defined daily dose
- 14.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/17/1196/003-008
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for sarilumab.
Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sarilumab · interactions on record
190 records
- 39 severe
- 144 moderate
- 7 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sarilumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceKEVZARA 200 mg, solution injectable en seringue préremplieSANOFI WINTHROP INDUSTRIE
- NetherlandsKevzara 200 mg, oplossing voor injectie in voorgevulde penSanofi Winthrop Industrie
- CzechiaKEVZARASanofi Winthrop Industrie, Gentilly
- BelgiumKevzara 150 mgSanofi Winthrop Industrie
- SwedenKevzara 150 mg Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- IcelandKevzaraSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- PolandKevzaraSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kevzara
- Liechtenstein · Kevzara
- Norway · Kevzara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7de08dab-ca3b-41a2-8b77-2f0bbd05ee02 GET /v1/drugs/7de08dab-ca3b-41a2-8b77-2f0bbd05ee02?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"L04AC",
"L04AC14"
],
"strength": null,
"pa_number": "EU/1/17/1196/003-008",
"substances": [
"Sarilumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about sarilumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.